BR112022011951A2 - Tratamento de esclerose lateral amiotrófica e distúrbios relacionados - Google Patents

Tratamento de esclerose lateral amiotrófica e distúrbios relacionados

Info

Publication number
BR112022011951A2
BR112022011951A2 BR112022011951A BR112022011951A BR112022011951A2 BR 112022011951 A2 BR112022011951 A2 BR 112022011951A2 BR 112022011951 A BR112022011951 A BR 112022011951A BR 112022011951 A BR112022011951 A BR 112022011951A BR 112022011951 A2 BR112022011951 A2 BR 112022011951A2
Authority
BR
Brazil
Prior art keywords
treatment
lateral sclerosis
amyotrophic lateral
related disorders
als
Prior art date
Application number
BR112022011951A
Other languages
English (en)
Inventor
Cohen Joshua
Klee Justin
Original Assignee
Amylyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylyx Pharmaceuticals Inc filed Critical Amylyx Pharmaceuticals Inc
Publication of BR112022011951A2 publication Critical patent/BR112022011951A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

TRATAMENTO DE ESCLEROSE LATERAL AMIOTRÓFICA E DISTÚRBIOS RELACIONADOS. São fornecidos no presente documento métodos e composições para tratar pelo menos um sintoma de ALS, desacelerando a progressão de doença de ALS ou reduzindo a deterioração de uma ou mais funções corporais afetadas por ALS em um sujeito. Os métodos podem incluir administrar ao sujeito um ácido de bile ou um sal farmaceuticamente aceitável do mesmo e um composto de fenilbutirato.
BR112022011951A 2019-12-16 2020-08-28 Tratamento de esclerose lateral amiotrófica e distúrbios relacionados BR112022011951A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962948770P 2019-12-16 2019-12-16
PCT/US2020/048581 WO2021126320A1 (en) 2019-12-16 2020-08-28 Treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
BR112022011951A2 true BR112022011951A2 (pt) 2022-09-06

Family

ID=72644870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011951A BR112022011951A2 (pt) 2019-12-16 2020-08-28 Tratamento de esclerose lateral amiotrófica e distúrbios relacionados

Country Status (12)

Country Link
US (9) US20210186990A1 (pt)
EP (1) EP4076419A1 (pt)
JP (1) JP2023507153A (pt)
KR (1) KR20220127832A (pt)
CN (1) CN114929209A (pt)
AU (1) AU2020407882A1 (pt)
BR (1) BR112022011951A2 (pt)
CA (1) CA3161244A1 (pt)
IL (1) IL293907A (pt)
MX (1) MX2022007276A (pt)
TW (1) TW202128183A (pt)
WO (1) WO2021126320A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3242378A1 (en) * 2022-01-28 2023-08-03 Roeland VANHAUWAERT Anti-musk antibodies for use in treating neuromuscular disorders
US12042476B2 (en) 2022-02-04 2024-07-23 Mcmaster University Methods for the treatment of lysosomal storage diseases
WO2023158641A1 (en) * 2022-02-15 2023-08-24 Retrotope, Inc. Synergistic combination therapy for treating als
US20230277630A1 (en) * 2022-03-02 2023-09-07 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
WO2023192406A2 (en) * 2022-03-30 2023-10-05 Retrotope, Inc. Prophylactic methods for treating als
WO2023220058A1 (en) * 2022-05-09 2023-11-16 Retrotope, Inc. Therapeutic methods for treating als
US20230364110A1 (en) * 2022-05-12 2023-11-16 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
WO2024054412A1 (en) * 2022-09-07 2024-03-14 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
US20240139211A1 (en) * 2022-09-29 2024-05-02 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
WO2024102114A1 (en) * 2022-11-07 2024-05-16 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating wolfram syndrome
WO2024105168A1 (en) 2022-11-18 2024-05-23 Inflectis Bioscience Novel combinations useful for the treatments of als

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2255812A1 (en) * 2004-11-01 2010-12-01 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
WO2011143152A2 (en) * 2010-05-11 2011-11-17 Questcor Pharmaceuticals Acth for treatment of amyotrophic lateral sclerosis
EP2422787A1 (en) * 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
EP2715350B1 (en) 2011-05-23 2017-09-27 Yeda Research and Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
SI3016654T1 (sl) * 2013-07-01 2019-05-31 Bruschettini S.R.L. Tauroursodeoksiholna kislina (TUDCA) za uporabo pri zdravljenju nevrodegenerativnih bolezni

Also Published As

Publication number Publication date
KR20220127832A (ko) 2022-09-20
JP2023507153A (ja) 2023-02-21
MX2022007276A (es) 2023-04-25
US20220152056A1 (en) 2022-05-19
US20220152057A1 (en) 2022-05-19
EP4076419A1 (en) 2022-10-26
WO2021126320A9 (en) 2021-10-07
WO2021126320A1 (en) 2021-06-24
CA3161244A1 (en) 2021-06-24
US20210186990A1 (en) 2021-06-24
US20220152053A1 (en) 2022-05-19
US20220152052A1 (en) 2022-05-19
US20220152058A1 (en) 2022-05-19
AU2020407882A1 (en) 2022-08-04
US20220152059A1 (en) 2022-05-19
CN114929209A (zh) 2022-08-19
IL293907A (en) 2022-08-01
TW202128183A (zh) 2021-08-01
US20220152055A1 (en) 2022-05-19
US20220152054A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
BR112022011951A2 (pt) Tratamento de esclerose lateral amiotrófica e distúrbios relacionados
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
BR112014010228A8 (pt) inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
BR112015023646A2 (pt) inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
MX2019004549A (es) Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений
BR112015019919A2 (pt) compostos bicíclicos
BR112012018765A2 (pt) agente profilático ou terapêutico para as doenças do trato biliar
BR112021020962A2 (pt) Métodos de tratamento de prurido
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112019018185A2 (pt) composição para tratar uma doença de articulação humana, e, kit.
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
AU2017261303A1 (en) Ophthalmic compositions
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
BR112015012497A2 (pt) combinações farmacêuticas

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]